Return to Results

A Randomized Phase III Trial Of Interferon Alfa-2B Or Interferon Alfa-2B Plus Bevacizumab In Patients With Advanced Renal Carcinoma

new search

Trial Conditions
  • Kidney Cancer
What is the purpose of this trial?

RATIONALE: Biological therapies, such as interferon alfa-2b, may interfere with the growth of tumor cells. Bevacizumab may stop the growth of tumor cells by stopping blood flow to the tumor. It is not yet known whether interferon alfa-2b is more effective with or without bevacizumab in treating advanced renal cell carcinoma (kidney cancer). PURPOSE: This randomized phase III trial is studying interferon alfa-2b and bevacizumab to see how well they work compared to interferon alfa-2b alone in treating patients with advanced renal cell carcinoma.

Date & Status

Active, not recruiting

Who can Participate?


18 and older




- Histologically or cytologically confirmed renal cell carcinoma (RCC)

- Conventional clear cell carcinoma

- Metastatic or unresectable disease

- The following characteristics and cellular types are excluded:

- True papillary

- Sarcomatoid features without a clear cell component

- Chromophobe

- Oncocytoma

- Collecting duct tumor

- Transitional cell carcinoma

- Measurable or nonmeasurable disease, including any of the following:

- Unidimensionally measurable lesion ≥ 20 mm by conventional techniques (e.g.,
physical exam or chest x-ray) OR 10 mm by spiral CT scan or MRI

- The following are considered nonmeasurable disease:

- Small lesions

- Bone lesions

- Leptomeningeal disease

- Ascites

- Pleural/pericardial effusion

- Lymphangitis cutis/pulmonis

- Abdominal masses that are not confirmed and followed by imaging techniques

- Cystic lesions

- Irradiated lesions, unless progression is documented after radiotherapy

- RCC paraffin tissue blocks or unstained slides must be available

- No evidence of prior or concurrent CNS metastases by MRI or CT scan



- 18 and over

Performance status

- Karnofsky 70-100%

Life expectancy

- Not specified


- Granulocyte count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- No history of clinically significant bleeding


- AST/ALT ≤ 2.5 times upper limit of normal (ULN)

- Alkaline phosphatase ≤ 2.5 times ULN

- Bilirubin ≤ 1.5 times ULN


- Creatinine ≤ 1.5 times ULN

- No proteinuria > 1+

- Proteinuria ≥ 2+ allowed provided protein is < 2 g/24-hour urine collection


- No deep venous thrombosis within the past year

- No cerebrovascular accident within the past year

- No peripheral vascular disease with claudication on < 1 block

- No uncontrolled hypertension defined as blood pressure ≥160 mm Hg (systolic) and/or ≥
90 mm Hg (diastolic) while on medication

- No New York Heart Association class II-IV congestive heart failure

- No angina pectoris requiring nitrate therapy

- No myocardial infarction within the past 6 months

- No other significant cardiovascular disease


- No pulmonary embolus within the past year

- No ongoing hemoptysis


- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 3 months after study

- No preexisting thyroid abnormality in which normal thyroid function cannot be
maintained by medication

- No delayed wound healing, ulcers, or bone fractures

- No uncontrolled psychiatric disorder

- No other currently active* malignancy except nonmelanoma skin cancer NOTE: *Disease
is not considered currently active if patient completed anticancer therapy and is
considered to have < 30% risk of relapse


Biologic therapy

- No prior systemic immunotherapy for RCC

- No prior thalidomide, anti-vascular endothelial growth factor (VEGF) therapy, VEGF
receptor inhibitors, or antiangiogenic treatment of any kind

- No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)


- No prior systemic chemotherapy for RCC

- No concurrent chemotherapy

Endocrine therapy

- No concurrent systemic corticosteroid therapy except the following:

- Topical and inhaled steroids

- Replacement therapy for adrenal insufficiency

- No concurrent hormones except those administered for nondisease-related conditions
(e.g., insulin for diabetes)


- See Disease Characteristics

- At least 4 weeks since prior radiotherapy and recovered

- Prior palliative radiotherapy to metastatic lesions allowed provided at least 1
measurable or nonmeasurable lesion remains untreated

- No concurrent palliative radiotherapy


- At least 4 weeks since prior major surgery and recovered


- No other prior systemic investigational therapy for RCC

- No other prior adjuvant or neoadjuvant systemic therapy for RCC

- No concurrent full-dose oral or parenteral anticoagulation* NOTE: *Low-dose (1 mg)
warfarin for maintenance of catheter patency and/or daily prophylactic aspirin is

Gender: Both
Steward Physician(s)
  • Brian I. Rini, MD
Trial Interventions
  • bevacizumab
  • recombinant interferon alfa
Physician Researcher

Investigator Name:

  • Brian I. Rini, MD

Other Information

Sponsor: Cancer and Leukemia Group B
Phase: Phase 3
Trial ID: NCT00072046
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2015 Steward Health Care
Connect Healthcare Panacea CMS Solutions